Navigation Links
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Date:12/20/2007

http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); and UniBody(R) are all trademarks of Genmab A/S.


'/>"/>
SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... 2011 Reportlinker.com announces that a new market ... Global Biotechnology Reagents Industry ... report analyzes the worldwide markets for Biotechnology Reagents ... Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, ...
... Feb. 23, 2011 Ingenuity® Systems, a leading ... science researchers, today announced a research collaboration with ... sequencing (NGS) data analysis. Covance Genomics Laboratory, a ... discovery and development industry, and Ingenuity will work ...
... State University have developed a faster, easier way ... by using liquid metal. Microfluidic devices manipulate small ... of applications, from testing minute blood samples to ... easier to incorporate electrodes into microfluidic devices, we ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Ingenuity Systems and Covance Collaborate to Support Next-Generation Sequencing Research 2Liquid metal key to simpler creation of electrodes for microfluidic devices 2
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
(Date:7/24/2014)... Neiker-Tecnalia is currently conducting research into the potato genes ... characterised by a reduction in rainfall and increased extremes ... the most resistant genes in order to create new ... conditions.The research is also seeking to find out how ... of greater drought and higher and lower temperatures. , ...
(Date:7/24/2014)... German . ... sufferers worldwide, a further 600 million people living with ... population contending with allergic rhinitis (allergic inflammation of the ... organs and parts of the body beyond the respiratory ... form of inflammatory bowel diseases such as colitis ulcerosa), ...
Breaking Biology News(10 mins):A tiny new species of frog from Brazil with a heroic name 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3
... of Genes & Development, Dr. Karlene Cimprich and colleagues ... sufficient to activate the ATR-mediated DNA damage checkpoint. ... Dr. Cimprich. "The ability to precisely define and manipulate ... experimental system will enable us to control, quantitative and ...
... to preserve grapes could help prevent allergies and boost healthy ... & Industry, the magazine of the SCI. The same technique ... wines without the added sulphites that can cause asthma and ... remain in storage for months and are usually treated with ...
... knowledge of the properties and actions of enzymes, scientists have ... originally isolated from blue-green algae. , This accomplishment is ... promising drugs for use in clinical trials. , In ... of the journal ACS Chemical Biology, a scientific team lead ...
Cached Biology News:Grape expectations for healthier wine 2Turning green gunk to gold, anti-cancer gold 2
... power of your ValveBank system! Program ... a Macintosh computer using graphic 'click-and-drag' timebars. ... print out program listings, then download your ... simple step., EasyCode is used for programming ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Fluoroskan Ascent is a dedicated ... for all kinds of assays ... and for clinical applications. Cell ... are all important application areas. ...
Biology Products: